AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01606176
Drug: GW-1000-02
RxNorm normalized name: GW-559090
DrugBank: GW-559090 (DB06508)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each actuation of GW-1000-02 (100 μl) delivered a dose containing 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose of study medication was eight actuations in any three hour period (20 mg THC/20 mg CBD) and 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
Trial: NCT01153711
Drug: BI 1744
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mcg solution for oral inhalation
Trial: NCT01153711
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg tablet
Trial: NCT02443246
Drug: Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01668446
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sildenafil tablets(50 mg) daily
Trial: NCT01668446
Drug: estradiol valerat
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00429676
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00602225
Drug: clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00602225
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01030952
Drug: Nateglinide
RxNorm normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
Trial: NCT01030952
Drug: Acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
Trial: NCT01545791
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered once or twice daily depending on patients' needs. Dose adjusted for each patient at the discretion of their treating physician
Trial: NCT01205932
Drug: Rivaroxaban (BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily dose: 5mg/day (5mg, once daily) for 34 to 35 days (±4 days)
Trial: NCT01205932
Drug: Rivaroxaban (BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily dose: 7.5mg/day (7.5mg, once daily) for 34 to 35 days (±4 days)
Trial: NCT01205932
Drug: Rivaroxaban (BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily dose: 10mg/day (10mg, once daily) for 34 to 35 days (±4 days)
Trial: NCT01205932
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily dose: 40mg/day (20mg each, twice daily) for 6 to 7 days (±2 days)
Trial: NCT00119769
Drug: Genotropin (human recombinant Growth hormone)
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotropin, 0.7 mg/day injected subcutaneously
Trial: NCT03572959
Drug: 0.1 % topical triamcinolone acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 % topical triamcinolone acetonide preparation was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application.
Trial: NCT00617058
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: open dosed, randomly assigned flexible dose treatment with 250-2000mg/day divided BID or TID
Trial: NCT00626509
Drug: sunitinib malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01391481
Drug: Sterile Water for Injection
RxNorm normalized name: Sterile Water For Injection
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of Sterile Water for Injection, 100ml/8h for 5 days
Trial: NCT00788892
Drug: CPX-351
RxNorm normalized name: CPX
DrugBank: DPCPX (DB12946)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00788892
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00788892
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02130661
Drug: Rilapladib 25 mg
RxNorm normalized name: Rilapladib
DrugBank: Rilapladib (DB05119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White, round, biconvex, film coated tablet of 25 mg. Taken orally along with food.
Trial: NCT05007899
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alternate day dosing of ferrous sulfate
Trial: NCT00656058
Drug: Singulair (Montelukast Sodium)
RxNorm normalized name: montelukast Chewable Tablet [Singulair]
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)
Trial: NCT00564902
Drug: 3R 3'R Zeaxanthin
DrugBank: Zeaxanthin (DB11176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg per day during 12 months
Trial: NCT04532294
Drug: BGB DXP593
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV) as specified in the treatment arm
Trial: NCT02561481
Drug: Sulforaphane
RxNorm normalized name: Sulforaphane
DrugBank: Sulforaphane (DB12422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See under active arm description
Trial: NCT00002552
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002552
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002552
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002552
Drug: perfosfamide
RxNorm normalized name: Perfosfamide
DrugBank: Perfosfamide (DB12727)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00332085
Drug: Chromium Picolinate
RxNorm normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03594747
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously as described
Trial: NCT03594747
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously as described
Trial: NCT03594747
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously as described
Trial: NCT03594747
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously as described
Trial: NCT00741897
Drug: Fexofenadine
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine: One 30 mg Tablet once daily for two weeks
Trial: NCT00861692
Drug: argatroban
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02097719
Drug: bimatoprost 0.01%
RxNorm normalized name: BIMATOPROST 0.01% OPH SOLN
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
Trial: NCT02097719
Drug: travoprost 0.004%
RxNorm normalized name: TRAVOPROST 0.004% SOLN,OPH
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Travoprost 0.004% administered to both eyes once daily for 12 weeks.
Trial: NCT02097719
Drug: timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol 0.5% administered to both eyes once daily for 12 weeks.
Trial: NCT02097719
Drug: hypromellose 0.3%
RxNorm normalized name: HYPROMELLOSE 0.3% GEL,OPH
DrugBank: Hypromellose (DB11075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
Trial: NCT02130661
Drug: Rilapladib 250 mg
RxNorm normalized name: Rilapladib
DrugBank: Rilapladib (DB05119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White, round, biconvex, film coated tablet of 250 mg. Taken orally along with food.
Trial: NCT02565758
Drug: ABBV-085
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an intravenous infusion in 28-day dosing cycles.
Trial: NCT02130661
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg capsule with a blue opaque cap and pink transparent body. Taken orally along with food.
Trial: NCT03802630
Drug: Brolucizumab 6 mg
RxNorm normalized name: BROLUCIZUMAB 6 mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [BEOVU]
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution for injection (intravitreal use)
Trial: NCT03802630
Drug: Aflibercept 2 mg
RxNorm normalized name: aflibercept 2 MG in 0.05 ML Injection
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution for injection (Intravitreal use)
Trial: NCT00537381
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m\^2 as intravenous infusion every 3 weeks.
Trial: NCT02507544
Drug: TRX-818 capsules
RxNorm normalized name: Trx-818 free acid
DrugBank: Foslinanib (DB16172)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00537381
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 5 mg orally twice daily.
Trial: NCT00712686
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, Oral, 15-30 mg, once daily, 140 weeks
Trial: NCT00712686
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, 10-20 mg, once daily, 140 weeks
Trial: NCT02511795
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AZD1775 will be given twice daily (PO BID) over 5 days (10 doses) on Days 1-5 and 8-12 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14.
Trial: NCT01949571
Drug: Mirtazapine (REMERON, Schering-Plough-Organon)
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the first and second phase of the study,the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, the mirtazapine group received 15 mg of mirtazapine.
Trial: NCT03177174
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: radiotherapy combined with Chemotherapy Drugs, Cancer
Trial: NCT02016716
Drug: Romosozumab 90 mg/mL
RxNorm normalized name: Romosozumab 90 mg/mL solution for injection
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).
Trial: NCT02016716
Drug: Romosozumab 70 mg/mL
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.
Trial: NCT00828802
Drug: Lenalidomide, Decitabine
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Decitabine 20mg/m2 over one hour IV for 5 days, with cycles repeated every 28 days. Lenalidomide given orally on Days 1-21 followed by 7 days of rest at various dose escalated cohorts (5 mg, 10mg, 15mg, 20 mg, 25 mg)
Trial: NCT01773005
Drug: Ofirmev
RxNorm normalized name: Ofirmev
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
Trial: NCT01773005
Drug: Caldolor
RxNorm normalized name: Caldolor
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
Trial: NCT02553551
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given.
Trial: NCT03177174
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel
Trial: NCT00731770
Drug: Advair 250 - matched
RxNorm normalized name: Advair
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: i puff bid inhaled
Trial: NCT03101488
Drug: KN035
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
Trial: NCT03512808
Drug: Ursodiol 500 MG
RxNorm normalized name: ursodiol 500 MG
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
Trial: NCT03512808
Drug: Urso Forte 500Mg Tablet
RxNorm normalized name: Urso Forte 500mg Tablet
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urso forte 500mg tablets followed by Ursodiol 500mg tablets
Trial: NCT03189615
Drug: Lu AF35700
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 10 mg Lu AF35700
Trial: NCT00661726
Drug: Decitabine (USAN, INN)
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 0.2 mg/kg of decitabine subcutaneously twice a week for 12 weeks. The dose will be reduced for toxicities as needed. The maximum dose of decitabine to be given will be 0.2 mg/kg.
Trial: NCT03533959
Drug: Alirocumab
RxNorm normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: the administration of Alirocumab at least 75mg every 2 weeks
Trial: NCT00426582
Drug: Patupilone
RxNorm normalized name: Patupilone
DrugBank: Patupilone (DB03010)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00086528
Drug: XL647
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally as a solution with mass-based dosing in early cohorts or as 50-mg tablets at a fixed dose at the MTD. A minimum of 3 subjects was planned for each dosing cohort with dose escalation dependent on subject tolerance of the prior dose. During the Treatment Period, subjects in each cohort were administered a single dose of XL647 on Day 1 followed by a 72-hour period of observation. If there were no XL647-related dose limiting toxicities, subjects received 5 daily doses of XL647 on Days 4-8. Twenty-one days after the initial dose, in the absence of unacceptable toxicity or disease progression, subjects could enter a Treatment Extension Period that consisted of repeated 2-week cycles of five oral doses of XL647 followed by a 9-day observation period.
Trial: NCT00540241
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: in-label use
Trial: NCT02147197
Drug: Ulipristal acetate (UPA)
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: UPA tablet
Trial: NCT01321255
Drug: FDC
RxNorm normalized name: FDCYD
DrugBank: 5-fluoro-2'-deoxycytidine (DB12957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC includes a combination of 100 mg aspirin, 40 mg simvastatin, and 2.5;5;10 mg Ramipril
Trial: NCT01198210
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local peritonsillar infiltration of 2 ml saline,
Trial: NCT01198210
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local peritonsillar infiltration of ketamine (0.5 mg/kg)
Trial: NCT01198210
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: local peritonsillar infiltration dexamethasone (0.2 mg/kg))
Trial: NCT01198210
Drug: ketamine-dexamethasone
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local peritonsillar infiltration combination of ketamine0.5mg/kg-dexamethason 0.2mg/kg
Trial: NCT00830375
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-30mg, by mouth, daily
Trial: NCT02326168
Drug: Bacillus Calmette-Guerin (BCG)
RxNorm normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation for non-muscle invasive bladder cancer
Trial: NCT00255918
Drug: Dimethoxybenzylidene anabaseine (DMXB-A)
RxNorm normalized name: Dimethoxybenzylidene anabaseine
DrugBank: GTS-21 (DB05708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
Trial: NCT00255918
Drug: Dimethoxybenzylidene anabaseine (DMXB-A)
RxNorm normalized name: Dimethoxybenzylidene anabaseine
DrugBank: GTS-21 (DB05708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
Trial: NCT04357730
Drug: Alteplase 50 MG [Activase]
RxNorm normalized name: alteplase 50 MG [Activase]
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 40 mgs over a total time of 2 hrs. Immediately following the Alteplase infusion, 5000 units (U) of unfractionated heparin (UFH) will be delivered and the heparin drip will be continued to maintain the activated partial thromboplastin time (aPTT) at 60-80sec (2.0 to 2.5 times the upper limit of normal). Re-bolusing of Alteplase, at the same dose, is permitted in the Alteplase-50 intervention group in those patients who show an initial transient response (\>20% improvement of PaO2/FiO2 over pre-infusion of Alteplase at any of the measurements at 2, 6, 12 or 18 hours, but \<50% improvement of PaO2/FiO2 at 24 hours after randomization); the repeat dose will be given between 24 and 36 hours after the initial Alteplase administration.
Trial: NCT04357730
Drug: Alteplase 50 MG [Activase]
RxNorm normalized name: alteplase 50 MG [Activase]
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: wed by the remaining 40 mgs over a total time of 2 hrs. Immediately following this initial Alteplase infusion, we will initiate a drip of 2 mg/hr Alteplase over the ensuing 24 hours (total 48 mg infusion) accompanied by an infusion of 500 units per hour (U/hr) heparin during the Alteplase drip. After this, heparin dose will be increased slowly to maintain aPTT between 60 and 80 sec, titrated per attending's discretion.
Trial: NCT01335893
Drug: Indocyanine Green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose will be diluted in saline solution. This will be a single dose given before the surgery intravenously.
Trial: NCT03419897
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT01012492
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
Trial: NCT02897037
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.